VECT - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to VectivBio's Conference Call to report Full Year 2021 Financial Results. My name is Livia, and I'll be your conference operator for today's call. [Operator Instructions] As a reminder, this call is being recorded at VectivBio's request.

Now, I would like to introduce your host for today's call, Claudia D’Augusta, Chief Financial Officer. ahead. go Please

Claudia D’Augusta

factors, ended press good which issued and company about Welcome forward-looking include of our today's full the of Harbor is and and risk everyone which SEC including in our summarizing that may to future those expectations, our review on Earlier Act Thank will morning, forward-looking that not to provide plans update statements remind we're our discussed website. from today's the this progress under a during Actual XXXX. year and a the the financial indicated the for by will across we statements prospects financial the constitute XX, materially morning, an these call important Private release statements provisions XXXX. Reform we factors differ our purposes filings, forward-looking you for like discussion results any Litigation statements. as results company, any obligation everyone. December available update under Securities and results to various I on would result of the Safe

who Joining me Chief our Officer that by Harris, Q&A, to Santarelli, we Medical based be are today point Basel the will is Khwaja, Officer, minutes, estimate in take our Omar joined our Kevin will in Officer. We will about open up Luca Chief remarks U.S. Chief and XX Executive we here then at Commercial which

Now over Luca. I'd to to like call turn the

Luca Santarelli

brief our you, today. with results joining I'll At to us and this company. everyone a financial to call, for Thank first begin Claudia, thanks introduction

drugs rare late-stage unmet with to biotech conditions new our is need. those story, company developing a transformational for For high VectivBio

a on industry patient. rare We veterans record focus expertise scientific successful a in are the in a relentless of track team deep diseases, with

considerable have is founding this to develop way to of XXXX, since we progress needs. achieving both to tailored our time identify therapeutics purpose. in short patient's and purpose a on and made our are transformational that In amount Our

Our a lead molecule apraglutide, is analog. next-generation GLP-X

programs, or unlock end and of pharmacology the X As a currently will GLP-X development graft-versus-host in of or full enhanced Phase therapeutic innovative short is in GvHD. Apraglutide believe representing failure SBS-IF intestinal Phase we disease apraglutide in action. result syndrome market potential in are mechanism both for markets, acute the and and X SBS-IF a for opportunity with GvHD bowel underserved apraglutide. blockbuster

is limited generation Regarding is SBS-IF established, approved poised significant [ph] this XXXX. in market to but There and only its Gattex. million under administration drug growth. revenues short of GLP-X estimated $XXX fiscal due believe Despite persistency analog the that burdensome yet first a an approximately SBS-IF, penetrated is one half-life regimen, year adoption add we called in for for Gattex a an

In broader well mortality. disease acute by subgroup results GvHD. patients, with in scientific end, interim Gattex. GI be a to in in first most use is that treatment to for suppressive where CIC study de-risk discoveries present to that nutrition apraglutide of limited complication recent supported that is in these to X the therapeutic patients of supporting as from adoption persistency. adoption improve significant approach SBS address This that potential our patient is demonstrate Our or a If improved and treatment with CIC. patients. leading have result absorption subgroup as this established leading there next results data apraglutide ahead non-immune critical GvHD, while the this damage, the this year, GLP-X just apraglutide the intestinal aims outcomes to can data promise few colon-in-continuity substantially for STARS aims offer positive of apraglutide we'll demonstrate -- SBS for may a And of ongoing goal Phase a is broader study to data better for To that the months,

Lastly, we take X results the well us proof-of-concept the in Phase main SBS GvHD. catalysts, our beyond study financial to in runway have and the

candidates, launch STARS achievement intestinal STARS important how of metabolic team targeting no clearance whom for for for And approved a affecting The inherited over of April. This business of potential apraglutide has program a XX,XXX patients; in the GvHD. The rare proud Comet, in year deals Japan our and patients initiation These Europe. with the the combined And platform platform Kreos treatment. I Pharmaceuticals in debt program, last even study a to later program, apraglutide in cash Phase and collectively provides class modular takes for CIC us. Kasei deal a study clinical is of within announced our diseases acquisition the just Now or year of Asahi progress of acute pivotal against can't and track drug the this patients of objectives, line overstate validation this pipeline successfully there we a multi-study study am in support stay Phase the results X designation apraglutide the our which looking successful drug nutrition off week, STARGAZE, report launched to SBS Phase back, will The molecule Europe. to details results enabled STARS we CIC and potential apraglutide, and I the also the that disease, the our approval IMD recruit to made for provide financial main interim the current was year, multiple we of enter partnership fuel a Capital. including orphan is a on in IPO currently beyond failure. enable of due U.S XXXX is great We Also by in the continue small with clinic us that with very key in XXXX significant our Since licensing XXXX. first beginning this two next which to year. geographic brought of start. has end a X X for the host strategy well Omar our external U.S AKP beyond versus will top during us best-in-class more us and to the recruiting catalyst. POC runway facility footprint pandemic. graft our on provide us to

like on the additional turn would who will pipeline our share programs. Omar, call our details Khwaja, Medical to to to Omar over I Chief Officer, Now, over you.

Omar Khwaja

Thanks, Luca, elaborate good like on I'd to clinical aspects apraglutide everyone. our further and morning, development of program. three

agonist; indicate goals autonomy, PS days the of majority for should competitors clinical demonstrate meaningful prospectively beginning intestinal calorie how finally, aims Firstly, increase Phase a believe the adoption. or that while to patients prescribers, to patient's STARS product. the to program we're post-surgical a In patients affords short meaningful full X not intestinal of to best-in-class while on action program in to other with maintenance a SBS by represents assessment a approach in and in deliver it apraglutide program that assessing physicians clinic. label stoma of value remnant SBS-IF We demonstrate based terms in intestinal We of STARS the program its and increased intestinal dosing CIC was hoc also where only a analog key patients. implemented Fundamentally, a is XXXX Patients distinct and also believe our or PS, differentiated other a program, with absorption to designed is and and PS GLP-X and the outcomes. in as only support increased dependency. the demonstrated and from and GLP-X And and developments into then and bowel to efficacy broader of with contingent and think SBS and selectivity, and [indiscernible] a absorption. improvements has there reduction the in in small connected want support allow we known weekly to last a to patients. potent intestinal secondary PS and GLP-X studies, epithelium we to Treatment that our based function; agonist, In of enhanced with support a SBS-IF greater that believe across ability greater efficacy that have could safety rationally on are tailored efficacy of required differentiation to steroids. gastrointestinal strategy GLP-Xs clinical barrier of to With non-immunosuppressive were on each support experience real-world the enable that reported measures compared increased outcomes that severe STARS acute increased number tolerability studies highly anatomy. of use, the colon, efficacy, which [indiscernible] studies, applications properties, payers. evidence, in novel STARS to remaining otherwise represent to approved as apraglutide be indications. with to previous pipeline on And better We're X is other volume of the is to will we patients' the impact half-life what and in preclinical on believe statistically has clinical patients SBS. validated. designing of and of GLP-X which regeneration, label clinically two experts weekly disease, may clinical healing to not heterogeneous Unlike lives. Phase Apraglutide trials, strategy, the evaluate We who understand Gattex will the colon-in-continuity head-to-head enhanced apraglutide and clinically differentiated hours. SBS-IF. wherever a small pharmacological of and colon-in-continuity We pre-specified post elimination improved pivotal as SBS-IF parenteral of subpopulation, primary effects liver designed GLP-X the potency novel in outcomes We have as that GLP-X and stoma and but disease STARS as dosing, versus failure the in first endpoints assessing now [ph] effects and the pursuing agonists, been intestine broad Gattex range On with is belief and assessments outcome disorders. stoma prospectively such, its patients mechanism differentiate CIC. analysis the the translate is reduce the have potentially response possible is mechanism provide GLP-X random apraglutide these SBS-IF, prioritized graft-versus-host well and do apraglutide significant was and in of receptor patient such in the and further an decade a pharmacological respond persistency when or option learned CIC. To patients proxy properties SBS-IF, XX that translate reduction the distinct to the bag, on subtypes the

XXX up kind, in addition, and of and and supplemental it detect improvements life power of first nutrition each total its in patients has of In SBS-IF over represent STARS patients, metabolic to population. a enteral XX with enrolling to of duration in study population. months, SBS XX% balance in CIC the autonomy to patients quality Rules

reporting study on results be in Scientific the of from of will the effects interim intestinal XXXX, absorption half including and this apraglutide We a second quantitative at Congress output. stool

intestinal data CIC out ongoing having since Phase benefit data X on patients. apraglutide's beta these X the de-risk apraglutide's PS substantially read to in potential STARS nutrition that requirements. already study year, With Phase believe the ahead outcomes in next it population, efficacy this to improvements reduction of the stoma demonstrated in highlight may has Should absorption we positively, the unique

comment the our pandemic. withstand Let update COVID conclude the designed faced operational strategy short that to with was the on during a me STARS challenges

stem And to countries, Asia XX total including of capabilities, far We stay class a This cell apraglutide end our track to across say able remote trial us for we're activated by to America. Phase non-immunosuppressive Europe Approximately U.S., the guidance enabled line regenerative Japan. data the occur GvHD. combined on in of treatment pleased we're Europe, STARS the broad steady annually also and out Apraglutide for recruitment. XX study top in and transplants sites, report first X footprint, XX,XXX as XX SBS-IF, developing and U.S., unique acute have so XXXX. from to the allogeneic has maintain South the spanned with I'm beyond

apraglutide symptoms are severe present comprises as Our develop X,XXX transplant, who around GvHD year. of diarrhea T and marrow gut and and large loss X group malabsorption months, driven of XX% GI gut apraglutide patients become estimate to severity damage it's from well a GvHD symptoms. barrier. survival the is by condition per rationale to two tract. results the The on murine part develop [Indiscernible] GI bone and These supported cause epithelium, for is of datasets. patients to in can the among GI GvHD, of these intestinal integrity first that experiment, GvHD. steroids, this results from acute increase target severe those Mortality cell the in the in donor model resulting severe of demonstrated as simple by with at we line of the refractory damage conditioning attacks in the patients

acute Phase U.S is in reduce showing GI GLP-X activated there clinical corticosteroids Europe, the refractory and proof-of-concept the GvHD. XXXX. refractory study half of epithelium look data patients the and in clearance can first obtained study expect coming evaluating and recently data published our addition, from forward promote the regulatory in with systemic reporting year, X GvHD. combination to apraglutide In We symptoms that patients first and with gut of weeks. in This steroid agonists with sites STARGAZE, our interim regeneration ruxolitinib in in this last study steroid is to dose and we've patients

look molecule about Turning for future. Since finally methylmalonic these very and With acidemia, to forward results. over to life of are Claudia? the XXXX D’Augusta progress and severe the treatment turn acidemia, acquisition pipeline, our I financial development to for in excited the now track Claudia limiting lead I we've updating clinic discuss call VB-XXXX into will We're and on the specifically you XXXX. CFO, made upcoming propionic our the entry that, our in organic our the rapid on promises platform, of the milestones the in to of of Comet.

Claudia D’Augusta

I the Omar. you, the Thank now for will briefly on financials comment XXXX. key year

personal the to million, approximately for XXXX. public approximate US$XX increase with as in was the for Our expenses million cost million our basis. increase million company. plan, million. well comprised and liability, includes increase R&D G&A related long-term in US$XX the which as due operating a million operating increase cost STARS to US$X related on costs accounting involved to a costs compared and We're preparation increase of of approximate XXXX were non-cash and encompasses recognition US$XX progress an to We the cash IPO in This XXXX in US$XX US$XXX of an of This expenses. G&A equity offsets cash contingent incentive equivalents as program, year-over-year certain mainly XX% ended

two financial the position. we mentioned, our week Luca strengthened announced as addition, last In deals significantly

sales in First, Japan. eligibility well our agreement collaboration development provides AKP milestones, a million US$XX royalties with upfront, as as apraglutide in for on downstream US$XXX plus of million

in line at credit Second, available our a our these end Capital, provide our capital us two US$XXX up top STARS up Together, flexible US$XXX and million providing with US$XX to million. XXXX combined facility beyond cash with transactions Kreos runway the to operating of results. of with million near-term to cash X Phase access extend

Now, hand I'd Luca. to call like back to the

Luca Santarelli

And to underscore close, following during covered to points. Thank of I'd a We the call. today's ground you, Claudia. lot like

has improved GLP-X potential we to next best-in-class patients which lead better our apraglutide generation leading a molecule for a in persistency. result that believe is profile, will adoption broader outcomes and First,

an is apraglutide growth. established yet market we believe but Secondly, poised for underserved is significant that entering

XXXX. it As a and syndrome, administration, in adoption one only is half-life due burdensome limited US$XXX fiscal short approve reminder, despite approximately there million generating year GLP-X bowel is for and short

patient If the the with holds label nutrition months, present program. our We reimbursement. aimed data Operator? optimize call to can so XXXX. will that development dose I'm the limited would Coupling year track to a positive, data STARS us when a Phase substantially of ongoing respond the improve we and first STARS the a also we aim to is GvHD on quarter, and the with there the program, the in during factors finally, STARS the understand results robust we're proof-of-concept top are to track our this supporting in why line STARGAZE that read excited Next, results GLP-X of in like next to Phase what at these ahead to interim de-risk demonstrate study runway from CIC provide half intestinal to has data set may the delivering use population in apraglutide the hospital on potential use. X just we those differentiated a our Also, able launch acute now data VectivBio. With apraglutide of for to patients, patient are through absorption X readout, study you future we for Gattex. is few that, indicate sure the financial about take open And and questions.

Operator

Thomas question SVB first from Instructions] our And [Operator of coming with Leerink. line the Smith

open. Your is line

Thomas Smith

for guys Hey, can hear Thanks me? you taking the questions. guys. Hey,

Luca Santarelli

Yes.

Thomas Smith

Okay, questions. all questions A the Congrats the great. deals. the Yes. on Thanks progress for of recent on two couple end. our taking and

positive nutrition First about any later your early you're guess through Thanks. a data volume? your Do the looks you on year? you more from this like to there? see just And talk look baseline? for have Can in any presentation us like see what's you the you I study. energy do be changes need this absorption to efficacy Just available here? expect STARS seeing data for little bit to idea perspective change a need from maybe set? statistically Or good data would set What results signals, a enrollment? what on Like PS expectations walk significant helpful. really And do

Luca Santarelli

question. the Thanks for

schedule. a well, later And study we anticipate at the this according to is reporting So, results conference. it's recruiting recruiting year

analysis full as far, on by seen we benefit run mature there the subset. letting is have so a opposed we what in are what the We believe incorrigible and and data to

remind shown clinical -- that a any in patients. hasn't GLP-X a like, let of have analog success looks prospective response been trials terms that in there defining of just the what me So, CIC study

what to to study absorption in so, readout, is interim parameters for CIC And do, absorption improve -- parameters the demonstrate at that least designed intestinal is can apraglutide the patients.

So, would and for an be our endpoint Phase trial. of [indiscernible] to reduce because you support, And to is X such which ability ability to the the effect parameters key know, as the improving fluids X study, Phase bode they nutrients well the such demonstrate unprecedented. would as is absorption drive primary

Thomas Smith

of we we That's expectation from helpful. just guess, is points clarify, Okay, Luca, temptations expect have And, study? nutrition I what would when kind STARS later point? guess available great. I this that that time cohort at it full data And of year, be the do to your see would that for evaluation you

Luca Santarelli

as we have is at had This patients And we and XX the it's that in XX-week X-week communicated an stoma will will GLP-Xs Yes, study the X-week stoma patients. performed same and used the without X a has metabolic same assessment. in X our been the before, as that Phase time assessment past of in out balance Type in point we look study. the

So, patients. time same are it's in is very patients to very to if our would CIC such treatment, absorption take promising, in stage in an longer a this an the at these improvement we to early again, -- again, early the do early respondents an such time, point. -- see At patients, because it anticipated

absorption parameters very will weeks, if response promising. So, we a in at this be see X

Thomas Smith

competitive about of just to Okay, deal rationale Can why AKP and Japan? ideal more was just process talk partner bit do and And you success with little got how process a on here? it. the Understood. kind Like strategic you drive the one AKP. the in the the quicker is think then a Japan

Luca Santarelli

question. that Thanks for

the a by to its that, to rationale we fold, primary to Japan. was the value partner. of wanted apraglutide that is but obviously, rationale access the needed wanted we accelerating for we that for Japanese deal, And the So, maximize it -- multiple

U.S recruiting launch implemented partners Phase to are we And to So, and we over X to markets. years, America, Asia, a the X key Europe. strategy, have where the we trial patients identify have with a this in ourselves the and other last in committed U.S Latin globally, commercial and strategy in keeping addition including to Europe for

provides Now, the our fuel this deal advantage business. cash near-term it us of with is other to that

have to that are we're before we're as near-term we As upfront commercial. additional the going sharing STARS get others getting million and in communicated, as And that later regulatory then going we're milestones get US$XX program and that the well in and right to there completion of cost development, away.

US$XXX up milestones. of million a to total in Now,

them, in approximately are rare with are GI, of development, and committed hematology, and a terms they have we And proven Western companies. to AKP why other of a were also medical drug is chosen immunology in them. generated this that in has hospital have reasons XXX their business. history a in why experience these countries they of Western expanding have successful and representatives long commercialization partnering that disease In and business with company products They are we chosen the commercializing

process. a several lastly, for offers to the was organized can't financial that, of had just was over product, terms was best We of this both partner, conclude, disclose with So but terms X competitive also our of in it led yes, a and products. details of competitive the the process, I which and to in last ran aspects. months compatibility the but choice our

Thomas Smith

Super taking it. thanks Luca yes, got thanks our and questions. guys helpful. Thanks, for -- Okay,

Luca Santarelli

Thank you.

Operator

America. Bank the from next our with Tazeen Ahmad of of line question coming And

Your line open. is

Tazeen Ahmad

Hi, good morning, guys. questions. Thanks for taking my

that GvHD, first treating read that there? ask think in secondly, looking the For to interim wanted from reading you maybe And of be half then are I consider Zealand have for what Thank about to out interim a the from for a candidate you you good the do means the that? study? [ph] I [indiscernible], what recent And you acute the or we on it Luca, article should to what appeared bowel I is with that read-through think think specifically in do products for CEO particular their you their that they're newspaper, apraglutide Danish and where syndrome highlighting Vectiv short talks think that what he you. attempt about particular

Luca Santarelli

Thanks question. for

we relevant going to are how Officer, interim have rest That Medical get endpoints to question. let's about I'm that Khwaja to first. read Okay, going the the respond describe the Omar what -- is our first in program the analysis, question GvHD, out the I yes. -- the are of what was Chief the will to and

Omar Khwaja

study Yes, maybe review mean, I Tazeen, what Thanks, just is. for right. the briefly question. the

interim, apraglutide So, a to and are proof-of-concept The derived patients of assessing acute reporting, fashion And day reach we pivotal initial the data, levels response from to benchmark blinded both of and Phase up XX looking against at XX steroid the comparators in X stage At study and partial of -- be about the control this XX with patients. overall two day partly external dose refractory to responses a to GvHD. at study in ruxolitinib. and external subset arm. patients we'll and that XX control XX

Tazeen Ahmad

Okay. And …

Luca Santarelli

Just data benchmark the from overall set patients know to from are expected on exactly obviously is XX at X the of going the day we rates -- study is and XX came lot at. obviously, includes XX. add And numbers. what top really about looking And that, to XXX that we're upon of the there and of improve to REACH be at Yes, responses course, And those that's what -- day complete partial a that's week and ruxolitinib. room

Tazeen Ahmad

Okay.

Luca Santarelli

All right.

to was Danish you interview from second second an about agree just you of question SBS's So, comment -- most that in agreed asset. close the and say valuable interview glepaglutide. think -- read-through we is mean, I company, And news context one communicate specifically more which asked can the the -- that underpenetrated. I thing in did one he out in I the comment the say Gattex a is in I where question, he communications but that public incredible that within ask former can the penetrated and it valuable consider on XX% then is was asked US$XXX million that, we CMO mentioned all is no me let as what and than they our the year. turnover that is won't was of CEO is thing glepaglutide like last the is I that media, new market of media also the the the of singled that say, Zealand,

next the think agree GLP-X So, and [indiscernible] is for opportunity us I -- SBS the generation I a that time. valuable would

Tazeen Ahmad

Okay, you. thank

Operator

question Our next …

Luca Santarelli

Yes. you. Thank

Operator

LifeSci Our line Dolezal next of from the question Capital. with Patrick coming

Your line open. is

Patrick Dolezal

Hi, thanks for taking the questions.

just, color STARS study just bit. it'd additional great you a be in little just So of nutrition if if delayed could was provide can, you terms a little why

to competing insights Just the therapy, about the largest two between rare it about curious we there? kind STARS being contributing prioritizing think are Is COVID, there's overlap condition? studies? then on if And just as how those been curious any factors enrollment [indiscernible] any enrollment enrollment. is just then study, And implications there a pivotal Thanks. and of you've

Luca Santarelli

not The clarify. me let Now delayed. study was

in letting far. full data it we on think is we But looking want there the to are -- so We be. for mature opposed a at data. the run subset to benefit track We where seen as and analysis are to encouraged what and we have of we

is so, with recruitment rather peer that conference as context review of anticipated. a the than have we decided we'll do actually study earlier. the the in doing it fall But And progress this the in

Patrick Dolezal

speak required renal provide with additional could unmet you helpful. are comorbidities using then Got the recently you Thanks. color dose subset, guess, patients suboptimal? was just that then considering the SBS-IF patients to apra? on these just in if also if it. and I presented just responses if data And And could in curious That's this reductions need, are patient's

Luca Santarelli

question. patient. Omar renal the impairment respond Yes, that Omar, I will about let

Omar Khwaja

Yes.

data and is to impairment. adjustments important that I particularly patients presentation with renal presented first even renal SBS-IF patients what same the But of that's of renal dose, flat that able whether that doesn't. that milligram apraglutide, in isn’t for requires moderate have which was patients with severe There our XX% dose. all, efficacy. whether makes dose on impairment that to -- of a it we a dose would we're a dose there, adjustment Gattex that So or X-milligram difference require severe with impairment the evidence not to the in flat us that to is, half with mean, use X

impaired we concern using about the moderate are what physicians renally patients. that impairment, with in concerns from think the you adjustment patients of range full it even without going adjustment, I at patients in SBS-IF. dose there And across severe we Gattex dose apraglutide data with be that about is to using a can is shows use think presented a that renal the and Aspen suitable hear to though we

Patrick Dolezal

for questions. Thanks Great. the taking

Operator

Tiago from Our next Instructions] with Suisse. of Fauth question [Operator Credit coming line the

open. is Your line

Tiago Fauth

for taking thanks Hey, the question.

question. perhaps So a potential and differentiation commercial

days prospectively how in it's what So, have establish versus lower impact in do the a And given to parenteral reduction where it patient important end reason have is of therapy? generics hard where don't I PS population, have terms in you could asked available. can they you baseline CIC potential that that up may scenario the number looking to actually the basically but to they light claims assess relative volumes, I that how of understand Gattex support that commercial is take have of

understand regimen? of key CIC to relative could Thank you. the differentiation dosing So just a to be point that trying selling how much better

Luca Santarelli

Okay.

guess I let's So, part this question.

a considering CIC absolute how do bit is in -- volume that perhaps have describe relevant. The -- first do benefit part less we is is an you

differentiate subtypes. benefit basis approximately our -- sets. volume have that you you the on objective as I say a subtypes. less look the reduction in large between XX% stated, a its to is these the data just me is XX% difference they of among important [ph] two correctly benefits outcomes therapeutic and if CIC, one, -- there different therapeutic is -- believe that That In volume infusion it described We number to across exactly these study. is and average, agree autonomical is it objective let there Okay, two the and how

evidence sepsis is parenteral goal so, dependency consequences risk population for the is you infusion, with our a this of basically means the way elimination days by and main risk week, to to associated goal And the and of And described in And establish enteral full remove enteral autonomy. that's of support the autonomy. the the from design. And which fewer that the greater our that all having of infusion as a -- remove been reduction program that. catheter, dwelling need study the of the of of you is

in big subgroups, of volume or this a establish for reduction expression analysis also we running in a we and stratified a further in study dependency are That's two some CIC. population, And enteral enteral of these into are accrue longer to a to the full there path that of in X objective of support, which the these towards why autonomy. that more is mere analysis patients achieve off, because secondary with is So, of have terms to CIC, -- doing parenteral a some in opportunity period conduct a months, months, we patients in of demonstrating GLP-X up we add days know cases the for and a effects amount XX can than especially autonomy. significant can not

So the that's to the answer question. first

generic -- of significant we will no best there to if will that disclosure this any know approvals The and There when there be second a still year? we question about of be limitations, no we was do [indiscernible] Gattex is scheduled is in what it apraglutide U.S. to [ph] generic will profile from differentiator Gattex Gattex a And not and think all a expire Gattex Why to the are [indiscernible] next the about point. market, believe of comes do if even it obsolete. of the generic that? possibility was I generics with like this its middle make then, with about at of and First a all, mechanism think

actually So, Officer to Kevin [indiscernible] we tell Kevin? Commercial these conducted would actually research, conclusions, our this conducted. Chief you about I Harris, research like we and payer to extensive

Kevin Harris

past engagement not some years We've position the appropriately question, this very Luca. payer over community. to payers we've exploring the but how apraglutide thanks, had standard X significant potential And from only of with insights care. got a important Yes, as future

of that a the that the in in appreciate payers, plans. today if launch, First generics GLP-X that is fact disease would the SBS-IF only nature today or further at and their today, exploration Gattex there's payers U.S. still to have will that may And clinical a product. launch. the generic launch branded as fact they of a treatment they that two for need fact exists believed they discount is one with month they And validate only same the obviously the also has they given SBS-IF, impact small profile about unmet acknowledged with therapy, modest treatment today very $XX,XXX In the much that branded patients a a in these budget very GLP-X and which do

differentiated all with most privatized value would a to the really launch become in apraglutide. they CIC particular, they when value of [indiscernible] we the say, greatest believe private delivering importantly, enteral the value I do we to in we've from the a stoma in payer data the particularly And obsolete the essentially the payers think I essentially regards and really profile, our efficacy stronger the delivering gotten with of that will a proposition. as both plan reinforce them fact is Gattex the that see feedback -- autonomy the product on community. In extra of show population population, data we

Tiago Fauth

the taking for again Thanks question. Perfect.

Operator

Thank showing I'll for turn remarks. you. And call Santarelli time. further over the back I'm at any this now Luca closing to questions

Luca Santarelli

And the you. on everybody today progress. looking to for has posted and everybody forward future thank earnings rest Thank our keeping I'm a our the who us in joined Have to I of good day. want call,

Operator

does you gentlemen, that and Ladies conference today. our for Thank conclude participation. your for

You may now disconnect.

VectivBio Holding (VECT) 7 Apr 222021 Q4 Earnings call transcript